Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint

Authors: Basch, Ethan M., Scholz, Mark, de Bono, Johann S., Vogelzang, Nicholas, de Souza, Paul, Marx, Gavin, Vaishampayan, Ulka, George, Saby, Schwarz, James K., Antonarakis, Emmanuel S., O'Sullivan, Joseph M., Kalebasty, Arash Rezazadeh, Chi, Kim N., Dreicer, Robert, Hutson, Thomas E., Dueck, Amylou C., Bennett, Antonia V., Dayan, Erica, Mangeshkar, Milan, Holland, Jaymes, Weitzman, Aaron L., Scher, Howard I.

Source: In European Urology June 2019 75(6):929-937

Summary Statement Novel Agents in the Treatment of Lung Cancer: Fifth Cambridge Conference Assessing Opportunities for Combination Therapy

Authors: Lynch, Thomas J., Jr, Blumenschein, George R., Jr, Engelman, Jeffrey A., Espinoza-Delgado, Igor, Govindan, Ramaswamy, Hanke, Jeff, Hanna, Nasser H., Heymach, John V., Hirsch, Fred R., Janne, Pasi A., Lilenbaum, Rogerio C., Natale, Ronald B., Riely, Gregory J., Sequist, Lecia V., Shapiro, Geoffrey I., Shaw, Alice, Shepherd, Frances A., Socinski, Mark, Sorensen, A Gregory, Wakelee, Heather A., Weitzman, Aaron

Source: In Journal of Thoracic Oncology June 2008 3(6) Supplement 2:S107-S112

MO38-1 Phase 1 study of ABBV-155 ± paclitaxel in relapsed/refractory solid tumors: Results in Japanese patients

Authors: Shimizu, Toshio, Yonemori, Kan, Kuboki, Yasutoshi, Tolcher, Anthony, Kurokawa, Misaki, Munasinghe, Wijith, Phillips, Andrew, Souers, Andrew, Johnson, Eric, He, Lei, Weitzman, Aaron, Powderly, John, Lorusso, Patricia, Naito, Yoichi

Source: In Annals of Oncology November 2023 34 Supplement 3:S1420-S1420

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

Authors: Kantarjian, Hagop M., Giles, Francis, Gattermann, Norbert, Bhalla, Kapil, Alimena, Giuliana, Palandri, Francesca, Ossenkoppele, Gert J., Nicolini, Franck-Emmanuel, O'Brien, Stephen G., Litzow, Mark, Bhatia, Ravi, Cervantes, Francisco, Haque, Ariful, Shou, Yaping, Resta, Debra J., Weitzman, Aaron, Hochhaus, Andreas, le Coutre, Philipp

Source: In Blood 15 November 2007 110(10):3540-3546

Methods of Using C-Met Modulators

Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer

Authors: Tiersten, Amy ^*, Wo, Jennifer, Jacobson, Caron, Weitzman, Aaron, Horwich, Tamara, Hesdorffer, Charles, Savage, David, Troxel, Andrea

Source: In The Breast 2004 13(4):341-346

DEXAMETHASONE DOES NOT SIGNIFICANTLY CONTRIBUTE TO THE RESPONSE RATE OF DOCETAXEL AND ESTRAMUSTINE IN ANDROGEN INDEPENDENT PROSTATE CANCER

Authors: WEITZMAN, AARON L., SHELTON, GARY, ZUECH, NANCY, OWEN, CINDY ENGLAND, JUDGE, TIMOTHY, BENSON, MITCHELL, SAWCZUK, IHOR, KATZ, AARON, OLSSON, CARL A., BAGIELLA, EMILIA, PFAFF, CHARLES, NEWHOUSE, JEFFREY H., PETRYLAK, DANIEL P.

Source: In The Journal of Urology 2000 163(3):834-837

Taxables take flight, push muni volume to new heights.

Authors: WEITZMAN, AARON (AUTHOR)

Source: Bond Buyer. 8/24/2020, Vol. 392 Issue 35365, pA3-A5. 3p. 5 Charts.

Subject Terms: *Bond prices, *Portfolio management (Investments), *Investments, *Municipal bonds, Flight

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by solid tumors in first-in-human phase 1 study.

Authors: Morelli, Maria Pia, Negrao, Marcelo Vailati, Collinson-Pautz, Matthew R., Jernigan, Kamisha, Demars, Nathan A., Weitzman, Aaron, Adeyemi, Frances, Carpio, Victor H, Jazaeri, Amir A., Johnson, Benny, Pant, Shubham, Kebriaei, Partow, Srivastava, Abhishek K, Deniger, Drew Caldwell, Heymach, John, Kopetz, Scott

Source: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p2547-2547, 1p

Volume Tops $31B For July.

Authors: WEITZMAN, AARON

Source: Bond Buyer. 8/2/2021, Vol. 393 Issue 35553, p1-18. 2p. 1 Graph.

Subject Terms: *Municipal bonds, *Public welfare, *COVID-19, Cities & towns, Older people

BAML Tops First-Half Rankings. (cover story)

Authors: WEITZMAN, AARON

Source: Bond Buyer. 7/10/2017, Vol. 389 Issue 34740, p1-21. 3p. 10 Charts.

Subject Terms: *Financial performance

Company/Entity: Bank of America Corp. Merrill Lynch , Public Financial Management Inc. 038006920 , Citigroup Inc. 197329691 C, J.P. Morgan Securities LLC , Morgan Stanley & Co. LLC

Wells Drops To Eighth In Ranking. (cover story)

Authors: WEITZMAN, AARON

Source: Bond Buyer. 4/11/2017, Vol. 1 Issue 34691, p1-19. 3p. 10 Charts.

Subject Terms: *Municipal finance, *Investment advisors -- Ratings & rankings

Company/Entity: Wells Fargo & Co. 006962435 WFC, Citigroup Inc. 197329691 C, Bank of America Corp. Merrill Lynch , J.P. Morgan Chase & Co.

New Market Forces Giving Bond Insurance a Lift.

Authors: WEITZMAN, AARON

Source: Bond Buyer. 6/4/2021, Vol. 393 Issue F614, pCover-3. 2p. 1 Graph.

Subject Terms: *Bond insurance, *COVID-19 pandemic, *Municipal bonds, *Corporate bonds, *Bonds (Finance), *Financial planning

Volume Took a Hit During May.

Authors: WEITZMAN, AARON

Source: Bond Buyer. 6/1/2021, Vol. 393 Issue 35519, pCover-22. 2p. 1 Chart, 1 Graph.

Subject Terms: *Bonds (Finance), *Municipal bonds, *Economic stimulus, *Federal aid, Bond refunding

Volume is Ahead of 2020's Pace.

Authors: WEITZMAN, AARON

Source: Bond Buyer. 5/3/2021, Vol. 393 Issue 35503, p1-14. 2p. 1 Chart.

Subject Terms: *Municipal bonds, *Revenue bonds, *Bonds (Finance), *Bond prices, *Office buildings, Fire stations

Volume Takes Off In March.

Authors: WEITZMAN, AARON

Source: Bond Buyer. 4/1/2021, Vol. 393 Issue 35486, p1-22. 2p. 1 Graph.

Subject Terms: *Municipal finance, *Municipal bonds, *Interest rates, *Bonds (Finance), *Bond prices, *Revenue bonds

This result is not displayed to guests.
Login for full access.